

# LIVER DIGEST

A weekly update of PLRC happenings

April 22, 2021



**PITTSBURGH LIVER  
RESEARCH CENTER**

A partnership of University of Pittsburgh & UPMC

[www.livercenter.pitt.edu](http://www.livercenter.pitt.edu)

*Please acknowledge support from the PLRC (NIH/NIDDK  
**P30DK120531**) in your publications and presentations. [\(Click for a  
copy/paste version for manuscript and grant submissions\)](#)*

## In this issue

- Faculty Highlights
  - Dr. Jian-Min Yuan publishes article in Obesity Science and Practice
  - Dr. David Geller publishes article in Cancer Letters
- Funding Opportunities
  - Pfizer Center for Therapeutic Innovation (CTIs)

---

### **Dr. Jian-Min Yuan published a manuscript in Obesity Science and Practice**

**Dr. Yuan**'s group published an article titled, "**Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease.**"

**Dr. Jaideep Behari**, also a PLRC member, is co-author on this manuscript, and Dr. Amir Borhani, PLRC P&F recipient also contributed to this study. **Click here for the full article on Pubmed.**

Behari J, Graham L, Wang R, Schirda C, Borhani AA, Methé BA, Li K, Morris A, Luu HN, Palmieri S, Yuan JM. Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease. *Obes Sci Pract.* 2021 Jan 4;7(2):217-225. doi: 10.1002/osp4.476. PMID: 33841891; PMCID: PMC8019274.

---

### **Dr. David Geller published a manuscript in Cancer Letters**

**Dr. Geller** published an article in Cancer Letters, entitled, "**Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC).**"

**[Click here for the Abstract and to view the Full Article.](#)**

Yan Y, Zheng L, Du Q, Yazdani H, Dong K, Guo Y, Geller DA. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett. 2021 May 28;506:95-106. doi: 10.1016/j.canlet.2021.03.002. Epub 2021 Mar 6. PMID: 33689775; PMCID: PMC8009854.

---

### **Update Information**

*Please continue to share your relevant accolades (grants, manuscripts, other news) with us, as it relates to PLRC mission, so we can share with all members. Please visit **[PLRC website here](#)** for up to date news, and upcoming seminar and event information. Contact AJ Singh ([singha16@upmc.edu](mailto:singha16@upmc.edu)) if you have specific questions or suggestions.*

---

### **FUNDING OPPORTUNITIES**

#### **Gilead Sciences Research Scholars Cardiovascular Comorbidities Program**

Gilead Sciences, Inc.

**To see all NIH Grants sorted by week, please visit: NIH Guide: 2021**

Or Click below:

- **[April 23](#)**
- **[April 16](#)**

[Click here for all current NIDDK Funding opportunities](#)

---

## **Pfizer Research Programs**

**Pfizer's Centers for Therapeutic Innovation (CTIs) are searching for new research programs within their strategic emerging scientific areas.**

- Oncology – Tumor Targeted, Immuno-Oncology, and Cancer Vaccines
- Internal Medicine – Obesity/Cachexia, Heart Failure, Diabetic/Chronic Kidney Disease, and NASH/T2D
- Inflammation & Immunology – Rheumatology, Gastroenterology, Medical Dermatology
- Rare Disease – Cardiology, Neuro-musc., Metabolic, Hematology

[Please click here for more information and to Apply.](#)

---

***Acknowledgment of Support Statement:*** This work was supported by NIH grant 1P30DK120531-01 to Pittsburgh Liver Research Center (PLRC)

---



*Copyright © 2019 Pittsburgh Liver Research Center, All rights reserved.*

**Our mailing address is:**

Pittsburgh Liver Research Center  
200 Lothrop St. | Pittsburgh, PA 15261